Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Neutralization After Antenatal Messenger RNA Vaccination

Amihai Rottenstreich; Olesya Vorontsov; Or Alfi; Gila Zarbiv; Esther Oiknine-Djian; Roy Zigron; Geffen Kleinstern; Michal Mandelboim; Shay Porat; Dana G Wolf

doi:10.1093/cid/ciac395

Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Neutralization After Antenatal Messenger RNA Vaccination

Clin Infect Dis. 2022 Nov 30;75(11):2023-2026. doi: 10.1093/cid/ciac395.

Authors

Affiliations

¹ Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
² Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
³ School of Public Health, University of Haifa, Haifa, Israel.
⁴ Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Ramat Gan, Israel.

Abstract

We evaluated the neutralization efficiency against SARS-CoV-2 Omicron variant in maternal and cord blood sera after antenatal BNT162b2 vaccination. Neutralizing antibodies against Omicron were lacking at the time of delivery after 2-dose vaccination. A third booster dose was essential in building neutralizing antibody capacity against Omicron among mothers and neonates.

Keywords: COVID-19; Omicron; SARS-CoV-2; pregnancy; vaccination.

MeSH terms

Antibodies, Neutralizing
Antibodies, Viral
BNT162 Vaccine
COVID-19* / prevention & control
Female
Humans
Infant, Newborn
Mothers
Pregnancy
Pregnancy Complications, Infectious* / prevention & control
RNA, Messenger
SARS-CoV-2 / genetics
Vaccination

Substances

RNA, Messenger
BNT162 Vaccine
Antibodies, Neutralizing
Antibodies, Viral

Supplementary concepts

SARS-CoV-2 variants